Bristol-Myers' Opdivo-Yervoy combo scores again at FDA, this time in colorectal cancer

Bristol-Myers Squibb's Opdivo picked up an approval in colorectal cancer last August. (Bristol-Myers Squibb)

Last August, Bristol-Myers Squibb’s Opdivo nabbed an indication in certain types of colorectal cancer. And Tuesday, it took a step toward nabbing that indication again—but this time alongside fellow BMS immunotherapy Yervoy.

U.S. regulators granted the Opdivo-Yervoy pairing priority review status in previously treated patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer. And now, Bristol is expecting an FDA decision by July 10.

If the FDA greenlights the duo, patients with the MSI-H or dMMR biomarkers—who make up between 4% and 5% of metastatic colorectal cancer patients and are less likely to benefit from conventional chemo—could potentially have a better treatment option from the New Jersey drugmaker.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

January study data showed that the tandem therapy provoked responses from 55% of patients, while solo Opdivo spurred a response in 31% of patients—though Bristol’s study, CheckMate-142, didn’t formally compare the two arms.

RELATED: Bristol-Myers Squibb's Opdivo nabs MSI-H colorectal cancer nod, but it can't match Keytruda's umbrella approval

A new Opdivo-Yervoy approval could also help Bristol extend its reach in a field where it's battling longtime foe Keytruda from Merck. Opdivo’s nemesis got a go-ahead in the patient population last May, but the one it received is broader; it covers solid tumors in any part of the body as long as they bear the MSI-H genetic features.

RELATED: Bristol-Myers' Opdivo-Yervoy team scores coveted win in first-line lung cancer

Meanwhile, BMS continues to rack up regulatory milestones for the Opdivo-Yervoy marriage, which already boasts FDA clearance in melanoma. All eyes are on the lung cancer field, though, where the one-two punch is vying for a piece of the lucrative first-line market.

Suggested Articles

Troubled Allergan is taking steps to appease investors, including bringing in a big-name biotech exec for guidance. But not everyone is impressed.

Bayer and J&J agreed to pay $775 million to wrap up about 25,000 lawsuits claiming their Xarelto anticoagulant caused severe bleeding.

The Monsanto acquisition "was and is a good idea," says Bayer chief executive, even as the company lost phase 1 of the first bellwether Roundup trial.